SCHEMBL14985494

SCHEMBL14985494

Clc1cccc(-c2cc(-c3ccccc3)[nH]n2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.70
RAB9A P51151 1/20 0.70
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
LMNA P02545 2/20 0.57
HPGD P15428 2/20 0.57
KMT2A Q03164 2/20 0.57
ALOX15 P16050 2/20 0.57
MAPK1 P28482 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HPGDS O60760 1/20 0.57
BCHE P06276 1/20 0.55
ACHE P22303 1/20 0.55
STAT3 P40763 1/20 0.52
STAT1 P42224 1/20 0.52
IDO1 P14902 1/20 0.51
HTT P42858 1/20 0.51
SAE1 Q9UBE0 2/20 0.49
UBA2 Q9UBT2 2/20 0.49
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22307330 0.93 POLB (0.70) POLBRAB9AMAPTMEN1LMNA
SCHEMBL8888245 0.93 POLB (0.58) POLBRAB9AMAPTMEN1LMNA
SCHEMBL8889610 0.88 RAB9A (0.72) POLBRAB9AMAPTMEN1LMNA
SCHEMBL8005401 0.87 POLB (0.53) POLBRAB9AMAPTMEN1LMNA
SCHEMBL20340353 0.87 RAB9A (0.84) POLBRAB9AMAPTMEN1LMNA
SCHEMBL6231163 0.84 RAB9A (0.79) POLBRAB9AMAPTMEN1LMNA
SCHEMBL15425079 0.84 POLB (0.49) POLBRAB9AMAPTMEN1LMNA
SCHEMBL22038895 0.84 MEN1 (0.53) POLBRAB9AMAPTMEN1LMNA
SCHEMBL15425061 0.84 MEN1 (0.53) POLBRAB9AMAPTMEN1LMNA
SCHEMBL15425114 0.84 POLB (0.49) POLBRAB9AMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788086-B1 SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS BOEHRINGER INGELHEIM INT (DE) 2016-10-12 EP disclosed
EP-2785696-B1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2015-09-23 EP disclosed
US-8822464-B2 N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-02 US disclosed
WO-2013083591-A1 SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 WO disclosed
WO-2013079460-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-06 WO disclosed
US-20130143870-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-06 US disclosed
US-20130137688-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137688-A1 NOVEL COMPOUNDS GRM5, GRIN1, GRM1 POLB 3835/4885RAB9A 665/4885MAPT 281/4885
US-20130143870-A1 NOVEL COMPOUNDS GRM5, GRM1, GRIK5 POLB 3617/4885RAB9A 732/4885MAPT 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.